Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A. is dated May 6, 2025. The report serves as a disclosure of a press release issued on the same date. The registrant is a foreign private issuer based in Marseille, France, and files annual reports under Form 20-F.
Financial Metrics
The provided filing text contains only the cover page and exhibit index. It does not include the content of the press release or any financial statements. Consequently, there is no data available regarding revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The filing text does not provide specific details on material changes versus prior periods. The nature of the disclosed event is limited to the existence of a press release dated May 6, 2025.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, risks, contingencies, and unusual items are not described in the provided text. The filing references a press release (Exhibit 99.1) but does not summarize its contents.
Key Facts for Investor Verification
- The filing is a Form 6-K referencing a press release dated May 6, 2025, which is not included in the provided text.
- No financial metrics or operational updates are present in the cover page data.
- Investors must locate and review Exhibit 99.1 (the Press Release) to understand the specific news or event triggering this filing.
- The report is signed by Jonathan Dickinson, Chairman of the Executive Board and CEO.